Saturday, July 11, 2026

Drug profile · INN

vonicog alfa

vonicog alfa (VEYVONDI) is a von willebrand factor exogenous protein.

EMA: approved Blood and blood forming organs (B02) B02BD10
Patents linked 0
Pipeline programs 4
News articles 0
Drug details — vonicog alfa
Class
Blood and blood forming organs (B02)
Route
Patents
0
Programs
4
Data quality
0.83

Quick answer

vonicog alfa (VEYVONDI) is a von willebrand factor exogenous protein.

Key facts

INN vonicog alfa
Brand VEYVONDI
Mechanism von Willebrand factor exogenous protein
Target von Willebrand factor
Therapeutic class Blood and blood forming organs (B02)
ATC code B02BD10

Mechanism of action

von Willebrand factor exogenous protein

Primary target: von Willebrand factor

Approval history

Authority Status Date
EMA approved

Pipeline programs

  1. 071102 Phase 3 · Baxalta Innovations · Hereditary severe von Willebrand Disease in children
  2. TAK-577-3001 Phase 3 · Takeda · severe von Willebrand Disease
  3. Vonicog Alfa Phase 3 · Takeda · Von Willebrand Disease (VWD)
  4. Vonicog alfa Phase 3 · Takeda · Von Willebrand Disease

Related & competitor drugs

  1. apixaban Blood and blood forming organs (B01)
  2. berotralstat Blood and blood forming organs (B06)
  3. bivalirudin Blood and blood forming organs (B01)
  4. c1 inhibitor (human) Blood and blood forming organs (B06)
  5. clopidogrel Blood and blood forming organs (B01)
  6. dabigatran etexilate Blood and blood forming organs (B01)

Frequently asked questions

What is vonicog alfa?

vonicog alfa (VEYVONDI) is a von willebrand factor exogenous protein.

What is the brand name for vonicog alfa?

VEYVONDI is a marketed brand name for vonicog alfa. Check FDA Drugs@FDA for the current US label holder and prescribing information.